Literature DB >> 18842668

Time-lapse mapping of cortical changes in schizophrenia with different treatments.

Paul M Thompson1, George Bartzokis, Kiralee M Hayashi, Andrea D Klunder, Po H Lu, Nancy Edwards, Michael S Hong, Michael Yu, Jennifer A Geaga, Arthur W Toga, Cecil Charles, Diana O Perkins, Joseph McEvoy, Robert M Hamer, Mauricio Tohen, Gary D Tollefson, Jeffrey A Lieberman.   

Abstract

Using time-lapse maps, we visualized the dynamics of schizophrenia progression, revealing spreading cortical changes that depend on the type of antipsychotic treatment. Dynamic, 4-dimensional models of disease progression were created from 4 repeated high-resolution brain magnetic resonance imaging scans of 36 first-episode schizophrenia patients (30 men/6 women; mean age: 24.2 +/- 5.1 SD years) randomized to haloperidol (HAL) (n = 15) or olanzapine (OLZ) treatment (n = 21), imaged at baseline, 3, 6, and 12 months (144 scans). Based on surface-based cortical models and point-by-point measures of gray matter volume, we generated time-lapse maps for each treatment. Disease trajectories differed for atypical versus typical neuroleptic drugs. A rapidly advancing parietal-to-frontal deficit trajectory, in HAL-treated patients, mirrored normal cortical maturation but greatly intensified. The disease trajectory advanced even after symptom normalization, involving the frontal cortex within 12 months with typical drug treatment. Areas with fastest tissue loss shifted anteriorly in the first year of psychosis. This trajectory was not seen with OLZ. Whether this association reflects either reduced neurotoxicity or neuroprotection cannot be addressed with neuroimaging; changes may relate to glial rather than neural components. These maps revise current models of schizophrenia progression; due to power limitations, the findings require confirmation in a sample large enough to model group x time interactions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18842668      PMCID: PMC2665155          DOI: 10.1093/cercor/bhn152

Source DB:  PubMed          Journal:  Cereb Cortex        ISSN: 1047-3211            Impact factor:   5.357


  71 in total

1.  Relationships between IQ and regional cortical gray matter thickness in healthy adults.

Authors:  Katherine L Narr; Roger P Woods; Paul M Thompson; Philip Szeszko; Delbert Robinson; Teodora Dimtcheva; Mala Gurbani; Arthur W Toga; Robert M Bilder
Journal:  Cereb Cortex       Date:  2006-11-21       Impact factor: 5.357

2.  The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys.

Authors:  Karl-Anton Dorph-Petersen; Joseph N Pierri; James M Perel; Zhuoxin Sun; Allan R Sampson; David A Lewis
Journal:  Neuropsychopharmacology       Date:  2005-09       Impact factor: 7.853

Review 3.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials.

Authors:  Jeffrey A Lieberman
Journal:  J Clin Psychiatry       Date:  2007-02       Impact factor: 4.384

4.  Association of DISC1/TRAX haplotypes with schizophrenia, reduced prefrontal gray matter, and impaired short- and long-term memory.

Authors:  Tyrone D Cannon; William Hennah; Theo G M van Erp; Paul M Thompson; Jouko Lonnqvist; Matti Huttunen; Timothy Gasperoni; Annamari Tuulio-Henriksson; Tia Pirkola; Arthur W Toga; Jaakko Kaprio; John Mazziotta; Leena Peltonen
Journal:  Arch Gen Psychiatry       Date:  2005-11

5.  Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine.

Authors:  M H Chakos; J A Lieberman; J Alvir; R Bilder; M Ashtari
Journal:  Lancet       Date:  1995-02-18       Impact factor: 79.321

6.  Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study.

Authors:  D H Mathalon; E V Sullivan; K O Lim; A Pfefferbaum
Journal:  Arch Gen Psychiatry       Date:  2001-02

7.  White matter abnormalities in first-episode schizophrenia or schizoaffective disorder: a diffusion tensor imaging study.

Authors:  Philip R Szeszko; Babak A Ardekani; Manzar Ashtari; Sanjiv Kumra; Delbert G Robinson; Serge Sevy; Handan Gunduz-Bruce; Anil K Malhotra; John M Kane; Robert M Bilder; Kelvin O Lim
Journal:  Am J Psychiatry       Date:  2005-03       Impact factor: 18.112

8.  Effects of antipsychotic drugs on neurogenesis in the forebrain of the adult rat.

Authors:  Hui-Dong Wang; Floyd D Dunnavant; Tabitha Jarman; Ariel Y Deutch
Journal:  Neuropsychopharmacology       Date:  2004-07       Impact factor: 7.853

Review 9.  Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenetic mechanism.

Authors:  B T Woods
Journal:  Am J Psychiatry       Date:  1998-12       Impact factor: 18.112

10.  Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia.

Authors:  Beng-Choon Ho; Nancy C Andreasen; Peg Nopoulos; Stephan Arndt; Vincent Magnotta; Michael Flaum
Journal:  Arch Gen Psychiatry       Date:  2003-06
View more
  38 in total

Review 1.  Neuroimaging in psychiatric disorders.

Authors:  Joseph C Masdeu
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

2.  The Center for Computational Biology: resources, achievements, and challenges.

Authors:  Arthur W Toga; Ivo D Dinov; Paul M Thompson; Roger P Woods; John D Van Horn; David W Shattuck; D Stott Parker
Journal:  J Am Med Inform Assoc       Date:  2011-11-10       Impact factor: 4.497

3.  Dissociable morphometric differences of the inferior parietal lobule in schizophrenia.

Authors:  Lena Palaniyappan; Peter F Liddle
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-03-28       Impact factor: 5.270

4.  Topological correction of brain surface meshes using spherical harmonics.

Authors:  Rachel Aine Yotter; Robert Dahnke; Paul M Thompson; Christian Gaser
Journal:  Hum Brain Mapp       Date:  2010-07-27       Impact factor: 5.038

Review 5.  Regional differences in the action of antipsychotic drugs: implications for cognitive effects in schizophrenic patients.

Authors:  Richard J Beninger; Tyson W Baker; Matthew M Florczynski; Tomek J Banasikowski
Journal:  Neurotox Res       Date:  2010-04-08       Impact factor: 3.911

6.  Voxelwise genome-wide association study (vGWAS).

Authors:  Jason L Stein; Xue Hua; Suh Lee; April J Ho; Alex D Leow; Arthur W Toga; Andrew J Saykin; Li Shen; Tatiana Foroud; Nathan Pankratz; Matthew J Huentelman; David W Craig; Jill D Gerber; April N Allen; Jason J Corneveaux; Bryan M Dechairo; Steven G Potkin; Michael W Weiner; Paul Thompson
Journal:  Neuroimage       Date:  2010-02-17       Impact factor: 6.556

7.  [Can long-term treatment with antipsychotic drugs lead to structural brain damage? Pro].

Authors:  V Aderhold; S Weinmann; C Hägele; A Heinz
Journal:  Nervenarzt       Date:  2013-09       Impact factor: 1.214

Review 8.  [Frontal brain volume reduction due to antipsychotic drugs?].

Authors:  V Aderhold; S Weinmann; C Hägele; A Heinz
Journal:  Nervenarzt       Date:  2015-03       Impact factor: 1.214

9.  Levels of Red Blood Cell Fatty Acids in Patients With Psychosis, Their Unaffected Siblings, and Healthy Controls.

Authors:  Suzanne Medema; Roel J T Mocking; Maarten W J Koeter; Frédéric M Vaz; Carin Meijer; Lieuwe de Haan; Nico J M van Beveren; René Kahn; Lieuwe de Haan; Jim van Os; Durk Wiersma; Richard Bruggeman; Wiepke Cahn; Carin Meijer; Inez Myin-Germeys
Journal:  Schizophr Bull       Date:  2015-09-18       Impact factor: 9.306

10.  Multivariate tensor-based morphometry on surfaces: application to mapping ventricular abnormalities in HIV/AIDS.

Authors:  Yalin Wang; Jie Zhang; Boris Gutman; Tony F Chan; James T Becker; Howard J Aizenstein; Oscar L Lopez; Robert J Tamburo; Arthur W Toga; Paul M Thompson
Journal:  Neuroimage       Date:  2009-11-06       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.